JPMorgan analyst Jessica Fye reiterated an Overweight rating and $75.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI)The analyst comments "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Intra-Cellular Therapies (ITCI) PT Lowered to $96 at RBC CapitalMay 7, 2024 12:44 PM Jefferies Positive on Intra-Cellular Therapies (ITCI): 'We like the setup ahead of the second MDD readout in late-Q2'May 7, 2024 8:00 AM Form 10-Q Intra-Cellular Therapies For: Mar 31May 7, 2024 7:44 AM Form 8-K Intra-Cellular Therapies For: May 07May 7, 2024 7:41 AM Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 16c ; Offers GuidanceMay 7, 2024 7:33 AM Intra-Cellular Therapies Reports First Quarter 2024 Financial ResultsMay 7, 2024 7:30 AM